Cargando…

Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.

Metastatic testicular germ cell tumours are cured in approximately 85% of patients using cisplatin-based combination chemotherapy. Patients who fail to respond have a poor prognosis, and there is a need for more effective treatments for cisplatin-resistant disease. In this study, it is shown that tw...

Descripción completa

Detalles Bibliográficos
Autores principales: Pera, M. F., Köberle, B., Masters, J. R.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033767/
https://www.ncbi.nlm.nih.gov/pubmed/7734313
_version_ 1782136909554778112
author Pera, M. F.
Köberle, B.
Masters, J. R.
author_facet Pera, M. F.
Köberle, B.
Masters, J. R.
author_sort Pera, M. F.
collection PubMed
description Metastatic testicular germ cell tumours are cured in approximately 85% of patients using cisplatin-based combination chemotherapy. Patients who fail to respond have a poor prognosis, and there is a need for more effective treatments for cisplatin-resistant disease. In this study, it is shown that two of four cell lines derived from human non-seminomatous testicular germ cell tumours are exceptionally sensitive to temozolomide, a new imidazotetrazine which can cross the blood-brain barrier in mice. In addition, three pairs of cisplatin-resistant sublines show little cross-resistance to temozolomide. These data suggest that temozolomide might have activity against non-seminomatous testicular germ cell tumours which have relapsed following cisplatin-containing chemotherapy, and could have a role in the treatment of patients with metastatic lesions in the brain.
format Text
id pubmed-2033767
institution National Center for Biotechnology Information
language English
publishDate 1995
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20337672009-09-10 Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. Pera, M. F. Köberle, B. Masters, J. R. Br J Cancer Research Article Metastatic testicular germ cell tumours are cured in approximately 85% of patients using cisplatin-based combination chemotherapy. Patients who fail to respond have a poor prognosis, and there is a need for more effective treatments for cisplatin-resistant disease. In this study, it is shown that two of four cell lines derived from human non-seminomatous testicular germ cell tumours are exceptionally sensitive to temozolomide, a new imidazotetrazine which can cross the blood-brain barrier in mice. In addition, three pairs of cisplatin-resistant sublines show little cross-resistance to temozolomide. These data suggest that temozolomide might have activity against non-seminomatous testicular germ cell tumours which have relapsed following cisplatin-containing chemotherapy, and could have a role in the treatment of patients with metastatic lesions in the brain. Nature Publishing Group 1995-05 /pmc/articles/PMC2033767/ /pubmed/7734313 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Pera, M. F.
Köberle, B.
Masters, J. R.
Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
title Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
title_full Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
title_fullStr Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
title_full_unstemmed Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
title_short Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
title_sort exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033767/
https://www.ncbi.nlm.nih.gov/pubmed/7734313
work_keys_str_mv AT peramf exceptionalsensitivityoftesticulargermcelltumourcelllinestothenewanticanceragenttemozolomide
AT koberleb exceptionalsensitivityoftesticulargermcelltumourcelllinestothenewanticanceragenttemozolomide
AT mastersjr exceptionalsensitivityoftesticulargermcelltumourcelllinestothenewanticanceragenttemozolomide